UCB transfers sales, marketing rights of Corifeo; Recordati pays €10 million

By Elaine Rigoli

Tampa, Fla., April 24 - UCB has reached an agreement with Recordati to transfer back the sales and marketing rights in Germany of Corifeo, an anti-hypertensive calcium channel blocker, for a payment to UCB of €10 million.

"This transaction is another step taken by UCB in its strategy to focus on innovation for specialists particularly in the fields of the central nervous system, inflammation (including allergy) and oncology," executive vice president global operations Bill Robinson said in a news release.

Recordati is a pharmaceutical group with headquarters in Milan, Italy.

UCB is a biopharmaceutical company based in Brussels, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.